|Awarded On||November 02, 2011|
|Title||Novel Strategy for Treatment of HER2-Positive Breast Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Francois X Claret|
Trastuzumab (Ttzm) is the most effective targeted therapy identified to date for treating patients with metastatic breast cancer. However, resistance to Ttzm is a major obstacle in the clinic. An effective treatment for Ttzm-resistant tumors has not yet been found; thus, many women with metastatic breast cancer will die. To obtain the full benefit of this new drug, we need to understand the mechanisms of drug resistance and develop new therapeutic approaches. JAB1 is a negative regulator of the cell-cycle inhibitor p27. JAB1-overexpressing tumors have a protective barrier against Ttzm-mediated up-regulation of p27. Indeed, JAB1 levels were found to be significantly higher in Ttzm-resistant...